Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by GunnerGon Jan 13, 2020 2:39pm
89 Views
Post# 30547469

No guarantee, not before BLA

No guarantee, not before BLA I understand Stups, some whos first language is French may have trouble understanding the presentation and wording used in the NR. 

What management is presenting, are separte events in a bulleted list.

Listed point 1 is the "anticipated filing of BLA".  No guarantee, management is anticipating its sumbmission.  Definition of anticipated - "regard as probable; predict.".  Remember, they haven't got the FDA required checks in place and its been two years.

Listed point 2, "expected completion" of partnership.  No guarantee of a partnership they are hopeful to get a deal. 

Also, you failed to highlight the most critical part of point 2; "if approval received".  Management is stating a partnership is hopeful; if the FDA approval is received.

Point 1 is a separate event, ie filing BLA.

Point 2 is another event, totally separate from the first.


Key Corporate and R&D Priorities for 2020

  • Anticipated filing of an amended BLA with FDA for Ryplazim for the treatment of congenital plasminogen deficiency in the first half of the year
  • Expected completion of a global marketing partnership for Ryplazim, and preparation for commercial launch of Ryplazim in the United States, if approval is received
<< Previous
Bullboard Posts
Next >>